<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03388788</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00017489</org_study_id>
    <nct_id>NCT03388788</nct_id>
  </id_info>
  <brief_title>Body Weight and Heart Health</brief_title>
  <official_title>Circadian Mechanisms of Cardiovascular Risk in Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multidisciplinary investigation examining the circadian mechanisms regulating
      cardiovascular risk in obesity. Specifically, in a valid circadian protocol, the
      investigators aim to study resting cardiovascular risk markers and the reactivity of
      circadian rhythms in these risk markers to standardized stressors in obesity. Furthermore,
      using an ingenious approach, the investigators propose to explore impairment in pre/post
      synaptic function in the cardiac left ventricle.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>5 Days</time_frame>
    <description>Beat-by-beat and ambulatory blood pressure measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>5 Days</time_frame>
    <description>Heart rate via 2-channel echocardiogram (ECG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epinephrine</measure>
    <time_frame>5 days</time_frame>
    <description>Venous Epinephrine to estimate sympathetic output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norepinephrine</measure>
    <time_frame>5 days</time_frame>
    <description>Venous Norepinephrine to estimate sympathetic output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cortisol</measure>
    <time_frame>5 days</time_frame>
    <description>Saliva cortisol to estimate sympathetic output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone</measure>
    <time_frame>5 days</time_frame>
    <description>Venous Aldosterone to estimate sympathetic output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocannabinoid</measure>
    <time_frame>5 days</time_frame>
    <description>Plasma endocannabinoid to estimate sympathetic regulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability (HRV)</measure>
    <time_frame>5 days</time_frame>
    <description>Analysis of HRV from 12-lead ECG to assess parasympathetic activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malondialdehyde (MDA) adducts</measure>
    <time_frame>5 days</time_frame>
    <description>Plasma MDA to measure oxidative stress and inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow Mediated Dilation (FMD)</measure>
    <time_frame>5 days</time_frame>
    <description>FMD to measure endothelial function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Necrosis Factor alpha (TNF-alpha)</measure>
    <time_frame>5 days</time_frame>
    <description>TNF-alpha to assess inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary blood flow</measure>
    <time_frame>5 days.</time_frame>
    <description>Radiolabeled water to measure coronary blood flow during PET Imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norepinephrine reuptake transport</measure>
    <time_frame>5 days.</time_frame>
    <description>Radiolabeled meta-hydroxyephedrine (mHED) to measure norepinephrine reuptake during PET Imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-adrenergic receptor density</measure>
    <time_frame>5 days.</time_frame>
    <description>Radiolabeled agonist (CGP12177) to measure beta-adrenergic receptors during PET Imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dual Emission X-ray Absorbance (DEXA) Body composition</measure>
    <time_frame>1 day</time_frame>
    <description>DEXA imaging to assess body composition.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Cardiovascular Risk Factor</condition>
  <condition>Circadian Dysregulation</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Normal Weight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy lean controls [18.5&lt;BMI&lt;25 kg/m2 and WC &lt;94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Overweight</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy obese [30≤BMI&lt;40 and waist circumference (WC) ≥94/80 (men and women respectively)] will participate in a 5-day circadian study protocol with PET imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET Imaging</intervention_name>
    <description>Positron Emission Tomography (PET) imaging for research.</description>
    <arm_group_label>Normal Weight</arm_group_label>
    <arm_group_label>Overweight</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Circadian Study Protocol</intervention_name>
    <description>5-day circadian study schedule</description>
    <arm_group_label>Normal Weight</arm_group_label>
    <arm_group_label>Overweight</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 35-65

          -  Lean and overweight (BMI 18.5-40kg/m2)

          -  Habitually sedentary

        Exclusion Criteria:

          -  History of smoking/tobacco use

          -  Insomnia

          -  Moderate to severe obstructive sleep apnea.

          -  Prior shift work within 6 months prior to the study.

          -  Prescription medications

          -  Drugs of abuse

          -  Acute, chronic, or debilitating medical condition (including diabetes, hypertension,
             and metabolic syndrome)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicole P Bowles, PhD</last_name>
    <phone>5033463808</phone>
    <email>circadian@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maya X Herzig, BA</last_name>
    <phone>5033463808</phone>
    <email>circadian@ohsu.edu</email>
  </overall_contact_backup>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Steven A. Shea</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Chronobiology Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

